(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2011 (10.02.2011)

PCT

(10) International Publication Number
WO 2011/015348 A2

(51) **International Patent Classification**:
C12Q 1/68 (2006.01)

(21) **International Application Number**:
PCT/EP2010/004761

(22) **International Filing Date**:
3 August 2010 (03.08.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
09167184.2 4 August 2009 (04.08.2009) EP

(71) **Applicants** *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **VIB VZW** [BE/BE]; Rijvisschestraat 120, B-9052 Gent (BE). **LIFE SCIENCE RESEARCH PARTNERS VZW** [BE/BE]; Campus Gasthuisberg, Herestraat 49, bus 913, B-3000 Leuven (BE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **FOERNZLER, Dorothee** [DE/CH]; Eisengasse 16, CH-5600 Lenzburg (CH). **DELMAR, Paul** [FR/CH]; Hammerstrasse 89, CH-4057 Basel (CH). **SCHERER, Stefan** [DE/CH]; Solothurnerstrasse 19, CH-4053 Basel (CH). **LAMBRECHTS, Diether** [BE/BE]; Ernest-Solvaystraat 55, B-3010 Kessel-lo (BE). **CARMELIET, Peter** [BE/BE]; Sappelenbos 10, B-3052 Blanden (BE).

(74) **Agent**: **MEIER, Jürgen**; Vossius & Partner, Siebertstraße 4, 81675 München (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/015348 A2

(54) **Title**: RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

(57) **Abstract**: The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.